Serotonin Syndrome

Categories: Cancer diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Serotonin Syndrome

MalaCards integrated aliases for Serotonin Syndrome:

Name: Serotonin Syndrome 58 54 17
Malignant Carcinoid Syndrome 71
Serotonergic Syndrome 58
Serotonin Toxidrome 58
Serotonin Toxicity 58
Serotonin Storm 58


Orphanet epidemiological data:

serotonin syndrome
Inheritance: Not applicable; Age of onset: All ages;


Orphanet: 58  
Rare neurological diseases

External Ids:

MESH via Orphanet 44 D020230
UMLS via Orphanet 72 C0699828
Orphanet 58 ORPHA43116
UMLS 71 C0024586

Summaries for Serotonin Syndrome

MalaCards based summary : Serotonin Syndrome, also known as malignant carcinoid syndrome, is related to neuroleptic malignant syndrome and depression. An important gene associated with Serotonin Syndrome is HTR3A (5-Hydroxytryptamine Receptor 3A), and among its related pathways/superpathways are Peptide ligand-binding receptors and cAMP signaling pathway. The drugs Rasagiline and Epinephrine have been mentioned in the context of this disorder. Affiliated tissues include pituitary, brain and heart, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 74 Serotonin syndrome (SS) is a group of symptoms that may occur with the use of certain serotonergic... more...

Related Diseases for Serotonin Syndrome

Diseases related to Serotonin Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 312)
# Related Disease Score Top Affiliating Genes
1 neuroleptic malignant syndrome 31.0 HTR3A HTR2A HTR1A CYP2D6
2 depression 30.5 SLC6A4 MAOA HTR2A HTR1A
3 fibromyalgia 30.2 SLC6A4 HTR3A HTR2A
4 tic disorder 30.0 SLC6A4 MAOA HTR2A
5 cocaine abuse 29.9 SLC6A4 MAOB HTR3A
6 hepatic encephalopathy 29.8 SST MAOB MAOA
7 mental depression 29.8 SLC6A4 OXT MAOA HTR3A HTR2A HTR1A
8 generalized anxiety disorder 29.7 SLC6A4 MAOA HTR3A HTR2A HTR1A CYP2D6
9 post-traumatic stress disorder 29.7 SLC6A4 MAOB MAOA HTR2A
10 hyperprolactinemia 29.7 SST HTR2A GHRH
11 bipolar disorder 29.6 SST SLC6A4 MAOA HTR3A HTR2A HTR1A
12 mood disorder 29.5 SLC6A4 MAOB MAOA HTR3A HTR2A HTR1A
13 small cell cancer of the lung 29.4 SST GAST CHGA
14 endogenous depression 29.3 SLC6A4 OXT MAOA HTR3A HTR2A HTR1A
15 attention deficit-hyperactivity disorder 29.2 SLC6A4 OXT MAOB MAOA HTR2A HTR1A
16 obsessive-compulsive disorder 29.0 SST SLC6A4 OXT MAOB MAOA HTR3A
17 parkinson disease, late-onset 28.8 TAC1 SLC6A4 MAOB MAOA HTR3A HTR2A
18 panic disorder 28.7 TAC1 SLC6A4 MAOA HTR3A HTR2A HTR1A
19 anorexia nervosa 28.6 SLC6A4 PYY OXT MAOA HTR2A HTR1A
20 major depressive disorder 28.5 TAC1 SST SLC6A4 OXT MAOB MAOA
21 diarrhea 28.4 TAC1 SST SLC6A4 PYY HTR3A GAST
22 migraine with or without aura 1 28.3 TAC1 SLC6A4 OXT MAOB MAOA HTR3A
23 constipation 28.1 TAC1 SST SLC6A4 PYY HTR3A GAST
24 carcinoid syndrome 28.0 SST PYY MEN1 IFNA2 HTR3A GHRH
25 anxiety 27.8 TAC1 SLC6A4 OXT MAOB MAOA HTR3A
26 schizophrenia 5 10.5 HTR2A HTR1A
27 tremor 10.5
28 tardive dyskinesia 10.5 HTR2A CYP2D6
29 hypertrophy of tongue papillae 10.5 CYP3A4 CYP2D6
30 myoclonus 10.5
31 postmenopausal atrophic vaginitis 10.4 OXT CYP2D6
32 alcoholic psychosis 10.4 SLC6A4 HTR2A
33 delusional disorder 10.4 HTR2A HTR1A CYP2D6
34 conidiobolomycosis 10.4 CYP3A4 CYP2D6
35 kleptomania 10.4 SLC6A4 MAOA HTR1A
36 barbiturate abuse 10.4 MAOB MAOA
37 hypoactive sexual desire disorder 10.4 OXT HTR2A HTR1A
38 drug psychosis 10.4 HTR2A HTR1A
39 duodenal benign neoplasm 10.4 SST CHGA
40 ampulla of vater neoplasm 10.4 SST CHGA
41 intermittent explosive disorder 10.4 SLC6A4 MAOA HTR2A
42 carotid body cancer 10.4 SST CHGA
43 body dysmorphic disorder 10.4 SLC6A4 MAOA HTR2A
44 cervical large cell neuroendocrine carcinoma 10.4 SST CHGA
45 phobia, specific 10.4 SLC6A4 MAOA HTR1A
46 drug-induced mental disorder 10.3 HTR2A HTR1A
47 inhibited male orgasm 10.3 SLC6A4 OXT HTR1A
48 encephalopathy, progressive, early-onset, with episodic rhabdomyolysis 10.3
49 bipolar i disorder 10.3 SLC6A4 HTR2A HTR1A
50 dissociative disorder 10.3 SLC6A4 OXT HTR2A

Comorbidity relations with Serotonin Syndrome via Phenotypic Disease Network (PDN):

Intestinal Obstruction

Graphical network of the top 20 diseases related to Serotonin Syndrome:

Diseases related to Serotonin Syndrome

Symptoms & Phenotypes for Serotonin Syndrome

GenomeRNAi Phenotypes related to Serotonin Syndrome according to GeneCards Suite gene sharing:

# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00381-A-1 9.28 HTR1A HTR3A SLC6A4
2 Decreased viability GR00381-A-3 9.28 HTR1A HTR3A SLC6A4
3 Decreased viability GR00402-S-2 9.28 HTR1A HTR3A SLC6A4

MGI Mouse Phenotypes related to Serotonin Syndrome:

# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.03 GHRH HTR1A HTR2A HTR3A MAOA MAOB
2 endocrine/exocrine gland MP:0005379 9.81 CHGA GAST GHRH HTR2A HTR3A MEN1
3 homeostasis/metabolism MP:0005376 9.8 CHGA GAST GHRH HTR1A HTR3A MAOA
4 nervous system MP:0003631 9.44 CHGA GHRH HTR1A HTR3A MAOA MAOB

Drugs & Therapeutics for Serotonin Syndrome

Drugs for Serotonin Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 142)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Rasagiline Approved Phase 4 136236-51-6 3052776
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
Mannitol Approved, Investigational Phase 4 69-65-8 453 6251
Prilocaine Approved Phase 4 721-50-6 4906
Nitric Oxide Approved Phase 4 10102-43-9 145068
Racepinephrine Approved Phase 4 329-65-7 838
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
Sodium citrate Approved, Investigational Phase 4 68-04-2
Tapentadol Approved Phase 4 175591-23-8 9838022
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
Pramipexole Approved, Investigational Phase 4 104632-26-0 59868 119570
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
16 Pharmaceutical Solutions Phase 4
17 Neuroprotective Agents Phase 4
18 Monoamine Oxidase Inhibitors Phase 4
19 Natriuretic Agents Phase 4
20 Epinephryl borate Phase 4
21 diuretics Phase 4
22 Hormones Phase 4
23 Psychotropic Drugs Phase 4
24 Calcium, Dietary Phase 4
25 Narcotics Phase 4
26 Analgesics, Opioid Phase 4
27 Analgesics Phase 4
28 Citrate Phase 4
29 Anesthetics Phase 4
30 Adjuvants, Anesthesia Phase 4
31 Anesthetics, Dissociative Phase 4
32 Anesthetics, General Phase 4
33 Anesthetics, Intravenous Phase 4
34 Excitatory Amino Acid Antagonists Phase 4
35 Excitatory Amino Acids Phase 4
36 Tranquilizing Agents Phase 4
37 Anti-Anxiety Agents Phase 4
38 Anticonvulsants Phase 4
39 calcium channel blockers Phase 4
40 Adrenergic Agents Phase 4
41 Neurotransmitter Agents Phase 4
42 Dopamine Agents Phase 4
43 Protective Agents Phase 4
44 Dopamine agonists Phase 4
45 S 20098 Phase 4
46 Antioxidants Phase 4
47 Hypnotics and Sedatives Phase 4
48 Antiparkinson Agents Phase 4
49 Central Nervous System Depressants Phase 4
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3

Interventional clinical trials:

(show top 50) (show all 65)
# Name Status NCT ID Phase Drugs
1 Overnight Switch From Rasagiline To Safinamide In Fluctuating Patients With Parkinson's Disease: A Tolerability And Safety Study Completed NCT03843944 Phase 4 Safinamide
2 Evaluation of Ureteral Patency in the Post-indigo Carmine Era Completed NCT02677623 Phase 4 Pyridium;Sodium Fluorescein;Mannitol
3 A Combination Study With Sub-Dissociative Ketamine and Fentanyl to Treat Moderate to Severe Pain in the Emergency Department Recruiting NCT03959852 Phase 4 Fentanyl;Ketamine
4 Safety and Efficacy of Pre-emptive Tapentadol vs Pregabalin in Post Operative Pain Following Unilateral Total Knee Arthroplasty- A Randomised, Double Blind, Active Control, Clinical Trial Recruiting NCT03604354 Phase 4 Tapentadol 100 MG Oral Tablet;Pregabalin 150mg
5 A Multicenter, Randomized, Double-blind, Placebo-controlled Study: Evaluation of the Efficacy and Safety of Agomelatine in the Treatment of Sleep Disorders and Depression in Patients With Parkinson's Disease Not yet recruiting NCT03977441 Phase 4 Agomelatine or PIacebo
6 Sandostatin (Octreotide LAR) May Lead to Clinical Improvement Through Receptor Occupation Optimisation A Prospective Interventional Trial of Patients With Neuro-endocrine Tumors With Carcinoid Syndrome Receiving Octreotide LAR Terminated NCT04140409 Phase 4 Sandostatin
7 A Pilot Study of FOLFOX in Combination With Bevacizumab in Patients With Advanced Neuroendocrine Tumors Unknown status NCT00227617 Phase 2, Phase 3 5-fluorouracil;leucovorin;oxaliplatin
8 A Multicenter, Long-term Extension Study to Further Evaluate the Safety and Tolerability of Telotristat Etiprate (LX1606) Completed NCT02026063 Phase 3 Telotristat etiprate
9 A Phase 3, Randomized, Placebo-controlled, Multicenter, Double-blind Study to Evaluate the Safety and Efficacy of Telotristat Etiprate (LX1606) in Patients With Carcinoid Syndrome Completed NCT02063659 Phase 3 Telotristat etiprate;Placebo
10 A Phase 3, Randomized, Placebo-controlled, Parallel Group, Multicenter, Double-blind Study to Evaluate the Efficacy and Safety of Telotristat Etiprate (LX1606) in Patients With Carcinoid Syndrome Not Adequately Controlled by Somatostatin Analog (SSA) Therapy Completed NCT01677910 Phase 3 Telotristat etiprate;Placebo-matching telotristat etiprate
11 A Randomized, Double-blind Placebo-controlled, Multicenter Phase III Study in Patients With Advanced Carcinoid Tumor Receiving Octreotide Depot and Everolimus 10 mg/Day or Octreotide Depot and Placebo Completed NCT00412061 Phase 3 Octreotide;Placebo;Everolimus
12 A Double Blind, Randomized Placebo Controlled Clinical Trial Investigating the Efficacy and Safety of Somatuline Depot (Lanreotide) Injection in the Treatment of Carcinoid Syndrome Completed NCT00774930 Phase 3 Lanreotide;Placebo
13 Randomized Phase III Clinical Trial of Lanreotide Combined With Telotristat Ethyl or Placebo for the First-line Treatment in Patients With Advanced Well Differentiated Small Intestinal Neuroendocrine Tumours (siNET) With Highly-functioning Carcinoid Syndrome Not yet recruiting NCT04065165 Phase 3 Telotristat Ethyl;Lanreotide
14 A Phase III, Prospective, Multicenter, Randomized, Open, Parallel Group Comparison of Lanreotide Autogel® (90 and 120 mg) Administered by Deep Subcutaneous Injection Every Four Weeks, With Sandostatin LAR Depot (20 and 30 mg) Administered by Intramuscular Injection, Every Four Weeks for Six Months, in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome Terminated NCT00092287 Phase 3 lanreotide Autogel (somatostatin analogue);Sandostatin long acting release (LAR) Depot (somatostatin analogue)
15 A Phase 2, Open-Label, Multi-Center, Serial Ascending-Dose, Dose-Finding Study to Evaluate the Safety and Tolerability of LX1606 in Subjects With Symptomatic Carcinoid Syndrome Completed NCT01104415 Phase 2 Telotristat etiprate
16 A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Ascending, Multidose Study To Determine Safety and Tolerability of Orally Administered LX1606 in Subjects With Symptomatic Carcinoid Syndrome Refractory to Stable-Dose Octreotide Long-Acting Release Depot Therapy Completed NCT00853047 Phase 2 Telotristat etiprate;Octreotide LAR Depot;Placebo
17 Phase II Trial Of Thalidomide In Patients With Low Grade Neuroendocrine Tumors (Carcinoid and Islet Cell Cancers) Completed NCT00027638 Phase 2 thalidomide
18 A Phase II Trial of Bay 43-9006 in Progressive Metastatic Neuroendocrine Tumors Completed NCT00131911 Phase 2 sorafenib tosylate
19 Phase II Study of PS-341 in Metastatic Neuroendocrine Tumors Completed NCT00017199 Phase 2 bortezomib
20 A Phase II Study of Protracted Infusional 5-Fluorouracil Plus Alpha Interferon for Advanced Metastatic Carcinoid Completed NCT00002470 Phase 2 fluorouracil
21 A Phase II Trial of ZD1839 (Iressa®) in Metastatic Neuroendocrine Tumors Completed NCT00075439 Phase 2 gefitinib
22 A Phase II Study of CCI-779 in Metastatic Neuroendocrine Carcinomas Completed NCT00093782 Phase 2 temsirolimus
23 A Pilot Phase I/II Trial of Enteral Wallstents for Colonic Obstruction in the Setting of Malignancy Completed NCT00004911 Phase 1, Phase 2
24 A Pilot Phase I/II Trial of Enteral Wallstents for Duodenal Obstruction in the Setting of Malignancy Completed NCT00004910 Phase 1, Phase 2
25 A Phase 2 Study of GW786034 (Pazopanib) in Advanced Low-Grade or Intermediate-Grade Neuroendocrine Carcinoma Completed NCT00454363 Phase 2 Pazopanib Hydrochloride
26 A Phase 2 Trial of Temsirolimus and Bevacizumab in Patients With Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
27 Phase II Study Of Bevacizumab And PEG Interferon Alpha-2b (PEG Intron) In Patients With Metastatic, Or Unresectable Carcinoid Tumors Completed NCT00055809 Phase 2
28 Phase II Trial of 2-Fluorouracil Recombinant Alpha-2a-Interferon and Intravenous Hydroxyurea With Filgrastim in Patients With Refractory GI Malignancies Grant Application Title: Parenteral Hydroxyurea: A Modulator in Pancreatic Cancer Completed NCT00019474 Phase 2 fluorouracil;hydroxyurea
29 Study of First-Line Therapy Comprising Leucovorin Calcium, Fluorouracil, and Irinotecan (FOLFIRI) in Patients With Progressive Locally Advanced or Metastatic Duodenal-Pancreatic Endocrine Tumors Completed NCT00416767 Phase 2 fluorouracil;irinotecan hydrochloride;leucovorin calcium
30 A Phase II Clinical and Biologic Study of AMG 706 and Octreotide in Patients With Low-Grade Neuroendocrine Tumors Completed NCT00427349 Phase 2 AMG 706;octreotide
31 A Randomised Phase II Study Comparing Capecitabine Plus Streptozocin With or Without Cisplatin Chemotherapy as Treatment for Unresectable or Metastatic Neuroendocrine Tumors Completed NCT00602082 Phase 2 capecitabine;cisplatin;streptozocin
32 Monitoring Telotristat Ethyl Inhibition of Tryptophan Hydroxylase (TPH) in Neuroendocrine Tumors Using ?-[11C]Methyl-L-tryptophan (AMT)-PET Recruiting NCT03453489 Phase 2 Telotristat Etiprate
33 A Phase 2 Study Evaluating a Proprietary Amino Acid Based Medical Food (Enterade®) in Patients With Quality of Life Limiting Diarrhea Due to Carcinoid Syndrome and Other Neuroendocrine Tumors (NET). Recruiting NCT03722511 Phase 2
34 Phase II Study of Single Agent Regorafenib in Patients With Advanced/Metastatic Neuroendocrine Tumors Active, not recruiting NCT02259725 Phase 2 regorafenib
35 Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors Active, not recruiting NCT01841736 Phase 2 Pazopanib;Pazopanib Hydrochloride
36 Phase II Randomised Trial to Assess Progression of Carcinoid Heart Disease in Patients Treated With Lutathera Therapy Compared to Best Supportive Care. Not yet recruiting NCT04039516 Phase 2 Lutathera
37 Open Label Study to Evaluate the Pharmacokinetics, Efficacy and Safety of Two Doses of an Octreotide Implant in Patients With Carcinoid Syndrome Terminated NCT00884715 Phase 1, Phase 2 Octreotide
38 Phase II, Open, Adaptive, Dose Escalating, Multicentre Titration Study to Assess the Efficacy and Safety of Repeated Subcutaneous Administration of Different Doses of BIM 23A760 in Patients With Carcinoid Syndrome Terminated NCT01018953 Phase 2 BIM 23A760
39 Phase II Study of Above-Label Octreotide-LAR in Patients With Insufficiently Controlled Carcinoid Syndrome Terminated NCT01886287 Phase 2 Octreotide LAR
40 Phase II Study of Depsipeptide in Metastatic Neuroendocrine Tumors Terminated NCT00084461 Phase 2 romidepsin
41 Phase II Study of Panitumumab in the Treatment of Carcinoid Syndrome Withdrawn NCT01172717 Phase 2 Panitumumab
42 Phase II Study of Vatalanib and Octreotide in Patients With Progressive Low-Grade Neuroendocrine Tumors Withdrawn NCT00227773 Phase 2 octreotide acetate;vatalanib
43 A Phase 1, Open-label, Non-randomised, Single-dose Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]-Telotristat Etiprate (LX1606) in Healthy Male Subjects Completed NCT01932528 Phase 1 500 mg [14C]-LX1606
44 Phase I Clinical Trial of Temsirolimus and Vinorelbine in Advanced Solid Tumors. Completed NCT01155258 Phase 1 temsirolimus;vinorelbine ditartrate
45 A Phase I, Open Label, Maximum Tolerated Dose-Finding Study to Evaluate the Safety and Tolerability of 90Y-DOTA-tyr3-Octreotide Administered by Intravenous Infusion to Children With Refractory Somatostatin-Receptor Positive Tumors Completed NCT00049023 Phase 1
46 Phase I Study to Evaluate the Combination Chemotherapy Regimen of Oxaliplatin Plus Irinotecan in Previously Treated Patients With Metastatic Gastrointestinal Cancer Completed NCT00003427 Phase 1 irinotecan hydrochloride;oxaliplatin
47 Phase I Study of Anti-IGF-1R Monoclonal Antibody, IMC-A12, and mTOR Inhibitor, Everolimus, in Advanced Low to Intermediate Grade Neuroendocrine Carcinoma Completed NCT01204476 Phase 1 Everolimus;Octreotide Acetate
48 A Phase I Study of UCN-01 in Combination With Irinotecan in Resistant Solid Tumor Malignancies (Part I) and in Triple Negative (ER-Negative, PgR-Negative, HER-2 Not-Amplified) Recurrent Breast Cancers (Part II) Completed NCT00031681 Phase 1 7-hydroxystaurosporine;irinotecan hydrochloride
49 A Phase I Trial of Herceptin and Interleukin-12 Completed NCT00004074 Phase 1
50 A Phase I Clinical and Biological Evaluation of Combined EGFR Blockade With Erlotinib and Cetuximab in Patients With Advanced Cancer Completed NCT00397384 Phase 1 cetuximab;erlotinib hydrochloride

Search NIH Clinical Center for Serotonin Syndrome

Inferred drug relations via UMLS 71 / NDF-RT 50 :

Interferon Alfa-2b

Genetic Tests for Serotonin Syndrome

Anatomical Context for Serotonin Syndrome

MalaCards organs/tissues related to Serotonin Syndrome:

Pituitary, Brain, Heart, Liver, Small Intestine, Kidney, Thyroid

Publications for Serotonin Syndrome

Articles related to Serotonin Syndrome:

(show top 50) (show all 1276)
# Title Authors PMID Year
Is tapentadol an advance on tramadol? 54 61
20092221 2009
[Serotonin syndrome associated with linezolid use: a case report]. 54 61
20013432 2009
Serotonin syndrome: a complex but easily avoidable condition. 54 61
18433663 2008
5-Hydroxytryptamine 1A receptors in the paraventricular nucleus of the hypothalamus mediate oxytocin and adrenocorticotropin hormone release and some behavioral components of the serotonin syndrome. 54 61
15743927 2005
The serotonin syndrome. 54 61
15635814 2004
Serotonin syndrome presenting as hypotonic coma and apnea: potentially fatal complications of selective serotonin receptor inhibitor therapy. 54 61
11889332 2002
Thieno[3,2-b]- and thieno[2,3-b]pyrrole bioisosteric analogues of the hallucinogen and serotonin agonist N,N-dimethyltryptamine. 54 61
10090793 1999
Treatment of the serotonin syndrome with cyproheptadine. 54 61
9696181 1998
Serotonin syndrome and drug combinations: focus on MAOI and RIMA. 54 61
9224903 1997
Serotonin syndrome complicating migraine pharmacotherapy. 54 61
8869767 1996
[Serotonin syndrome in acute poisoning with antidepressive agents]. 54 61
9033760 1996
Brainstem 5-hydroxytrytamine1A binding sites are not down-regulated by agonists which induce tolerance in the rat: myoclonus and other serotonergic behaviors. 54 61
1387164 1992
Adolescent Polypharmacy and Serotonin Syndrome. 61
31934921 2020
Use of Cyproheptadine for the Treatment of Serotonin Syndrome: A Case Series. 61
31860612 2020
Behavioral effects of citalopram, tramadol, and binary mixture in zebrafish (Danio rerio) larvae. 61
31425864 2020
Drug-Drug Interactions (DDIs) in Psychiatric Practice, Part 8: Relative Receptor Binding Affinity as a Way of Understanding the Differential Pharmacology of Currently Available Antidepressants. 61
31913969 2020
Efficacy and safety of duloxetine and Pregabalin in Iranian patients with diabetic peripheral neuropathic pain: a double-blind, randomized clinical trial. 61
31890684 2019
Triptan and ergotamine overdoses in the United States: Analysis of the National Poison Data System. 61
31792093 2019
Development of severe serotonin syndrome from acute ingestion of vilazodone without co-ingestion. 61
31902699 2019
The role of chronic nutritional supplements consumption in a fulminant serotonin syndrome due to citalopram intoxication. 61
29317102 2019
Serotonin syndrome following left ventricular assist device implantation: A report and institution-specific strategy for prevention. 61
31762837 2019
Black Seed Oil and Perioperative Serotonin Syndrome: A Case Report. 61
31577540 2019
Metoclopramide-induced Serotonin Syndrome. 61
31938643 2019
Serotonin Syndrome in an Adolescent Girl. 61
31804878 2019
Serotonin Syndrome in the Emergency Department. 61
31938599 2019
Oral fenugreek seed consumption and serotonin syndrome. 61
31379190 2019
[Diagnostics and treatment of selected clinically relevant, acute drug intoxications]. 61
31578621 2019
Life-Threatening Serotonin Syndrome Due to Methylene Blue-Citalopram Interaction. 61
30855287 2019
Serotonin syndrome from sertraline monotherapy: A case report. 61
31837902 2019
Vilazodone poisoning: a systematic review. 61
31777303 2019
Unexpected Serotonin Syndrome, Epileptic Seizures, and Cerebral Edema Following 2,5-dimethoxy-4-bromophenethylamine Ingestion. 61
31643086 2019
Serotonin Toxicity: Associated Agents and Clinical Characteristics. 61
31688388 2019
Drug-Drug Interactions (DDIs) in Psychiatric Practice, Part 7: Relative Receptor Binding Affinity as a Way of Understanding the Differential Pharmacology of Currently Available Antipsychotics. 61
31821222 2019
Venlafaxine plus melatonin ameliorate reserpine-induced depression-like behavior in zebrafish. 61
31518687 2019
Serotonin syndrome masquerading as disease flare in lupus nephritis with end-stage renal disease. 61
31424178 2019
Citalopram overdose and severe serotonin syndrome in an intermediate metabolizing patient. 61
31257122 2019
Fentanyl-Associated Serotonin Syndrome and Chest Wall Rigidity in an Intensive Care Unit Patient. 61
29965805 2019
GHB roller-coaster: serotonin syndrome and withdrawal. 61
31596835 2019
Serotonin Syndrome in ICU-A Road Less Traveled. 61
31485108 2019
Differential role of dose and environment in initiating and intensifying neurotoxicity caused by MDMA in rats. 61
31383036 2019
Serotonin syndrome triggered by postoperative administration of serotonin noradrenaline reuptake inhibitor (SNRI). 61
32025920 2019
Takotsubo Cardiomyopathy: Medical and Psychiatric Aspects. Role of Psychotropic Medications in the Treatment of Adults with "Broken Heart" Syndrome. 61
31423403 2019
Recognizing Movement Disorder Emergencies - A Practical Review For Non-Neurologist. 61
31535526 2019
Drug-Drug Interactions (DDIs) in Psychiatric Practice, Part 6: Pharmacodynamic Considerations. 61
31291209 2019
Focal seizure as a manifestation of serotonin syndrome: case report. 61
31404205 2019
Effects of Epacadostat on Brain Extracellular Fluid Concentrations of Serotonin-an Intracerebral Microdialysis Study in Sprague-Dawley Rats. 61
31010933 2019
Fatal overdose with a combination of SNRIs venlafaxine and duloxetine. 61
30796754 2019
Multivisceral Failure in a Context of Serotonin Syndrome Induced by MDMA: The Investigation of a Unique and Nationwide Network. 61
31188157 2019
A Case of Serotonin Syndrome Caused by the Concomitant Utilization of Methylene Blue and Venlafaxine in an Oncological Patient. 61
31232145 2019
Serotonin Syndrome Following Tramadol and Gabapentin Use After Spine Surgery. 61
30898741 2019

Variations for Serotonin Syndrome

Expression for Serotonin Syndrome

Search GEO for disease gene expression data for Serotonin Syndrome.

Pathways for Serotonin Syndrome

Pathways related to Serotonin Syndrome according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
11.71 SLC6A4 CYP3A4 CYP2D6
Show member pathways
Show member pathways
Show member pathways
10.7 HTR3A CYP3A4 CYP2D6
Show member pathways
11 10.64 MAOB MAOA
Show member pathways
13 10.36 MAOA CYP2D6

GO Terms for Serotonin Syndrome

Cellular components related to Serotonin Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.61 TAC1 SST PYY OXT IFNA2 GHRH
2 integral component of presynaptic membrane GO:0099056 9.43 SLC6A4 HTR3A HTR2A
3 integral component of postsynaptic membrane GO:0099055 9.33 SLC6A4 HTR3A HTR2A
4 extracellular region GO:0005576 9.32 TAC1 SST PYY OXT NOTCH1 IFNA2

Biological processes related to Serotonin Syndrome according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.91 SST SLC6A4 MAOB HTR2A
2 neuropeptide signaling pathway GO:0007218 9.77 TAC1 SSTR1 PYY
3 memory GO:0007613 9.74 SLC6A4 OXT HTR2A
4 chemical synaptic transmission GO:0007268 9.72 TAC1 SST HTR3A HTR2A HTR1A
5 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.69 SSTR1 HTR2A HTR1A
6 cell-cell signaling GO:0007267 9.65 TAC1 SST IFNA2 GHRH CGB3
7 vasoconstriction GO:0042310 9.61 SLC6A4 HTR1A
8 oxidative demethylation GO:0070989 9.59 CYP3A4 CYP2D6
9 positive regulation of ossification GO:0045778 9.58 TAC1 OXT
10 positive regulation of renal sodium excretion GO:0035815 9.58 TAC1 OXT
11 sleep GO:0030431 9.56 OXT HTR2A
12 behavior GO:0007610 9.55 HTR2A HTR1A
13 neurotransmitter catabolic process GO:0042135 9.54 MAOB MAOA
14 response to steroid hormone GO:0048545 9.54 SST OXT MAOB
15 dopamine catabolic process GO:0042420 9.52 MAOB MAOA
16 heterocycle metabolic process GO:0046483 9.49 CYP3A4 CYP2D6
17 drug catabolic process GO:0042737 9.48 CYP3A4 CYP2D6
18 monoterpenoid metabolic process GO:0016098 9.46 CYP3A4 CYP2D6
19 sperm ejaculation GO:0042713 9.43 SLC6A4 OXT
20 alkaloid catabolic process GO:0009822 9.4 CYP3A4 CYP2D6
21 response to food GO:0032094 9.33 OXT GHRH GAST
22 G protein-coupled receptor signaling pathway GO:0007186 9.32 TAC1 SSTR1 SST PYY OXT HTR2A
23 serotonin receptor signaling pathway GO:0007210 9.13 HTR3A HTR2A HTR1A

Molecular functions related to Serotonin Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.35 SST PYY OXT GAST CGB3
2 neuropeptide hormone activity GO:0005184 9.33 PYY OXT GHRH
3 primary amine oxidase activity GO:0008131 9.26 MAOB MAOA
4 serotonin binding GO:0051378 8.92 SLC6A4 HTR3A HTR2A HTR1A

Sources for Serotonin Syndrome

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....